Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 10/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989128 | 0.93 | ALDH1A1 (0.43) | TSHRALDH1A1NAMPTCYP2C9 | |
| SCHEMBL9989094 | 0.89 | TSHR (0.42) | TSHRALDH1A1NAMPTCYP2C9LMNA | |
| SCHEMBL1580390 | 0.89 | TSHR (0.39) | TSHRALDH1A1NAMPT | |
| SCHEMBL9988058 | 0.88 | CYP2C9 (0.40) | TSHRALDH1A1NAMPTCYP2C9LMNA | |
| Fumaric Acid SCHEMBL1278082 | 0.88 | HDAC1 (0.36) | TSHRALDH1A1NAMPTCYP2C9 | |
| Fumaric Acid SCHEMBL1278086 | 0.88 | HDAC1 (0.36) | TSHRALDH1A1NAMPTCYP2C9 | |
| SCHEMBL9988642 | 0.86 | TSHR (0.41) | TSHRALDH1A1NAMPTLMNA | |
| SCHEMBL9988101 | 0.84 | NAMPT (0.45) | TSHRALDH1A1NAMPTCYP2C9 | |
| SCHEMBL1278515 | 0.84 | NAMPT (0.40) | TSHRALDH1A1NAMPTLMNA | |
| SCHEMBL9989088 | 0.82 | NTRK1 (0.46) | TSHRALDH1A1NAMPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299261-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110301173-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301173-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | GHSR, HRH2, ASNS | TSHR 287/4885ALDH1A1 1975/4885NAMPT 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.